Neurotransmitters and energy metabolites in amyloid-bearing APP SWExPSEN1dE9 mouse brain

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 2, 2010, Pages 364-370

  Hartmann, Joachim ^a   Kiewert, Cornelia ^a   Klein, Jochen ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMYLOID; CHOLINESTERASE; GLUCOSE; GLUTAMIC ACID; GLYCEROL; NEUROTRANSMITTER; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CHOLINE UPTAKE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENERGY METABOLISM; ENZYME ACTIVITY; HIPPOCAMPUS; MALE; MICRODIALYSIS; MOUSE; MOUSE STRAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ACETYLCHOLINE; AMYLOID; ANIMALS; BRAIN; CEREBRAL CORTEX; CHOLINE; CHOLINESTERASES; ENERGY METABOLISM; GLUCOSE; GLUTAMIC ACID; GLYCEROL; HIPPOCAMPUS; LACTIC ACID; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; SCOPOLAMINE; SENILE PLAQUES; SYNAPTOSOMES;

EID: 76749086956     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.161091     Document Type: Article

References (45)

1. Abbott JJ, Howlett DR, Francis PT, and Williams RJ (2008) Abeta(1-42) modulation of Akt phosphorylation via α7 nAChR and NMDA receptors. Neurobiol Aging 29:992-1001.
2. Apelt J, Kumar A, and Schliebs R (2002) Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human β-amyloid precursor protein. Brain Res 953:17-30.
3. Bell KF and Cuello AC (2006) Altered synaptic function in Alzheimer's disease. Eur J Pharmacol 545:11-21.
4. Bellucci A, Luccarini I, Scali C, Prosperi C, Giovannini MG, Pepeu G, and Casamenti F (2006) Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis 23:260-272.
5. Blass JP, Gibson GE, and Hoyer S (2002) The role of the metabolic lesion in Alzheimer's disease. J Alzheimers Dis 4:225-232.
6. Blennow K, de Leon MJ, and Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403.
7. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, and Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939-945.
8. Burns A and Iliffe S (2009) Alzheimer's disease. BMJ 338:467-471.
9. Bussière T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, and Buttini M (2004) Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance. Am J Pathol 165:987-995.
10. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, and Sweatt JD (2001) Betaamyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21:4125-4133.
11. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schüssel K, and Müller WE (2003) Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 66:1627-1634.
12. Fellows LK, Boutelle MG, and Fillenz M (1992) Extracellular brain glucose levels reflect local neuronal activity: a microdialysis study in awake, freely moving rats. J Neurochem 59:2141-2147.
13. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, and Frosch MP (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516-524.
14. Gau JT, Steinhilb ML, Kao TC, D'Amato CJ, Gaut JR, Frey KA, and Turner RS (2002) Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am J Pathol 160:731-738.
15. Gioanni Y, Rougeot C, Clarke PB, Lepousé C, Thierry AM, and Vidal C (1999) Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci 11:18-30.
16. Goto Y, Niidome T, Hongo H, Akaike A, Kihara T, and Sugimoto H (2008) Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Eur J Pharmacol 583:84-91.
17. Hardy J and Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
18. Hartmann J, Erb C, Ebert U, Baumann KH, Popp A, König G, and Klein J (2004) Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. Neuroscience 125:1009-1017.
19. Hascup KN, Hascup ER, Pomerleau F, Huettl P, and Gerhardt GA (2008) Second-by-second measures of L-glutamate in the prefrontal cortex and striatum of freely moving mice. J Pharmacol Exp Ther 324:725-731.
20. Hynd MR, Scott HL, and Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45:583-595.
21. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific secretase. Hum Mol Genet 13:159-170.
22. Kar S, Slowikowski SP, Westaway D, and Mount HT (2004) Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 29:427-441.
23. Kirvell SL, Esiri M, and Francis PT (2006) Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 98:939-950.
24. Klein J (2000) Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 107:1027-1063.
25. Kopf SR, Buchholzer ML, Hilgert M, Löffelholz K, and Klein J (2001) Glucose plus choline improve passive avoidance behaviour and increase hippocampal acetylcholine release in mice. Neuroscience 103:365-371.
26. Li B, Stribley JA, Ticu A, Xie W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs SH, and Lockridge O (2000) Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 75:1320-1331.
27. Liu L, Herukka SK, Minkeviciene R, van Groen T, and Tanila H (2004) Longitudinal observation on CSF Aβ42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis 17:516-523.
28. Löffelholz K and Klein J (2006) Precursors: choline and glucose, in The Brain Cholinergic System in Health and Disease (Giacobini E and Pepeu G eds) pp 75-83, Informa Healthcare, London.
29. Lowe SL, Bowen DM, Francis PT, and Neary D (1990) Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 38:571-577.
30. Machová E, Jakubík J, Michal P, Oksman M, Iivonen H, Tanila H, and Dolezal V (2008) Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice. Neurobiol Aging 29:368-378.
31. Marchi M and Raiteri M (1989) Interaction acetylcholine-glutamate in rat hippocampus: involvement of two subtypes of M-2 muscarinic receptors. J Pharmacol Exp Ther 248:1255-1260.
32. Marklund N, Salci K, Lewén A, and Hillered L (1997) Glycerol as a marker for post-traumatic membrane phospholipid degradation in rat brain. Neuroreport 8:1457-1461.
33. McGowan E, Eriksen J, and Hutton M (2006) A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 22:281-289.
34. McNay EC and Gold PE (1999) Extracellular glucose concentrations in the rat hippocampus measured by zero-net-flux: effects of microdialysis flow rate, strain, and age. J Neurochem 72:785-790.
35. Messier C and Gagnon M (1996) Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res 75:1-11.
36. Mesulam M (2006) The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem 10:43-49.
37. Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, Goldsteins G, Iivonen H, Leguit N, Glennon J, Koistinaho J, et al. (2008) Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem 105:584-594.
38. Mosconi L, Pupi A, and De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 1147:180-195.
39. Pellerin L and Magistretti PJ (2004) Neuroenergetics: calling upon astrocytes to satisfy hungry neurons. Neuroscientist 10:53-62.
40. Ragozzino ME, Unick KE, and Gold PE (1996) Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci U S A 93:4693-4698.
41. Rawls SM and Mcginty JF (1998) Muscarinic receptors regulate extracellular glutamate levels in the rat striatum: an in vivo microdialysis study. J Pharmacol Exp Ther 286:91-98.
42. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, and Borchelt DR (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to β-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18:602-617.
43. Schliebs R and Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 113:1625-1644.
44. Schurr A (2006) Lactate: the ultimate cerebral oxidative energy substrate? J Cereb Blood Flow Metab 26:142-152.
45. van der Zeyden M, Oldenziel WH, Rea K, Cremers TI, and Westerink BH (2008) Microdialysis of GABA and glutamate: analysis, interpretation and comparison with microsensors. Pharmacol Biochem Behav 90:135-147.